Singapore markets open in 1 hour 25 minutes
Straits Times Index
3,247.76 -35.59 (-1.08%) S&P 500
4,356.45 -53.68 (-1.22%) Dow
34,297.73 -66.77 (-0.19%) Nasdaq
13,539.29 -315.83 (-2.28%) BTC-USD
36,898.20 +336.02 (+0.92%) CMC Crypto 200
831.82 +11.23 (+1.37%)
Coherus BioSciences, Inc. (CHRS)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EST
After hours:
| Previous close | 12.74 |
| Open | 12.72 |
| Bid | 11.95 x 1200 |
| Ask | 12.29 x 900 |
| Day's range | 12.01 - 12.58 |
| 52-week range | 11.94 - 22.22 |
| Volume | |
| Avg. volume | 728,524 |
| Market cap | 943.693M |
| Beta (5Y monthly) | 0.92 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.12 |
| Earnings date | 22 Feb 2022 - 28 Feb 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 25.43 |
- Zacks
Coherus' (CHRS) Toripalimab Gets Orphan Drug Tag for Rare Cancer
The FDA bestows an Orphan Drug designation to Coherus (CHRS) and partner Junshi's toripalimab for the treatment of esophageal cancer.
- Motley Fool
Coherus BioSciences, inc (CHRS) Q3 2021 Earnings Call Transcript
Image source: The Motley Fool. Coherus BioSciences, inc (NASDAQ: CHRS)Q3 2021 Earnings CallNov 8, 2021, 5:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day, and thank you for standing by.
- Zacks
Coherus BioSciences (CHRS) Reports Q3 Loss, Misses Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -22.50% and -5.13%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
© 2022 Yahoo. All rights reserved.
